Marktanalyse - Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016

Global Markets Direct
12.2016
1475 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia — Pipeline Review, H2 2016, provides an overview of the Acute Myelocytic Leukemia (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 15, 91, 90, 1, 6, 143, 22 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 14, 14, 24 and 10 molecules, respectively.

Acute Myelocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Myelocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (Oncology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 10

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Overview 11

Therapeutics Development 12

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Development by Companies 14

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes 32

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Products Glance 35

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Development by Companies 39

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Investigation by Universities/Institutes 72

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development 77

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment 287

Drug Profiles 336

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 1388

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 1408

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 1415

Appendix 1428





List of Tables

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2016 58

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H2 2016 59

Number of Products under Development by Companies, H2 2016 61

Number of Products under Development by Companies, H2 2016 (Contd..1) 62

Number of Products under Development by Companies, H2 2016 (Contd..2) 63

Number of Products under Development by Companies, H2 2016 (Contd..3) 64

Number of Products under Development by Companies, H2 2016 (Contd..4) 65

Number of Products under Development by Companies, H2 2016 (Contd..5) 66

Number of Products under Development by Companies, H2 2016 (Contd..6) 67

Number of Products under Development by Companies, H2 2016 (Contd..7) 68

Number of Products under Development by Companies, H2 2016 (Contd..8) 69

Number of Products under Development by Companies, H2 2016 (Contd..9) 70

Number of Products under Development by Companies, H2 2016 (Contd..10) 71

Number of Products under Development by Companies, H2 2016 (Contd..11) 72

Number of Products under Development by Companies, H2 2016 (Contd..12) 73

Number of Products under Development by Companies, H2 2016 (Contd..13) 74

Number of Products under Development by Companies, H2 2016 (Contd..14) 75

Number of Products under Development by Companies, H2 2016 (Contd..15) 76

Number of Products under Development by Companies, H2 2016 (Contd..16) 77

Number of Products under Investigation by Universities/Institutes, H2 2016 78

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 79

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 80

Comparative Analysis by Late Stage Development, H2 2016 81

Comparative Analysis by Clinical Stage Development, H2 2016 82

Comparative Analysis by Early Stage Development, H2 2016 83

Comparative Analysis by Unknown Stage Development, H2 2016 84

Products under Development by Companies, H2 2016 85

Products under Development by Companies, H2 2016 (Contd..1) 86

Products under Development by Companies, H2 2016 (Contd..2) 87

Products under Development by Companies, H2 2016 (Contd..3) 88

Products under Development by Companies, H2 2016 (Contd..4) 89

Products under Development by Companies, H2 2016 (Contd..5) 90

Products under Development by Companies, H2 2016 (Contd..6) 91

Products under Development by Companies, H2 2016 (Contd..7) 92

Products under Development by Companies, H2 2016 (Contd..8) 93

Products under Development by Companies, H2 2016 (Contd..9) 94

Products under Development by Companies, H2 2016 (Contd..10) 95

Products under Development by Companies, H2 2016 (Contd..11) 96

Products under Development by Companies, H2 2016 (Contd..12) 97

Products under Development by Companies, H2 2016 (Contd..13) 98

Products under Development by Companies, H2 2016 (Contd..14) 99

Products under Development by Companies, H2 2016 (Contd..15) 100

Products under Development by Companies, H2 2016 (Contd..16) 101

Products under Development by Companies, H2 2016 (Contd..17) 102

Products under Development by Companies, H2 2016 (Contd..18) 103

Products under Development by Companies, H2 2016 (Contd..19) 104

Products under Development by Companies, H2 2016 (Contd..20) 105

Products under Development by Companies, H2 2016 (Contd..21) 106

Products under Development by Companies, H2 2016 (Contd..22) 107

Products under Development by Companies, H2 2016 (Contd..23) 108

Products under Development by Companies, H2 2016 (Contd..24) 109

Products under Development by Companies, H2 2016 (Contd..25) 110

Products under Development by Companies, H2 2016 (Contd..26) 111

Products under Development by Companies, H2 2016 (Contd..27) 112

Products under Development by Companies, H2 2016 (Contd..28) 113

Products under Development by Companies, H2 2016 (Contd..29) 114

Products under Development by Companies, H2 2016 (Contd..30) 115

Products under Development by Companies, H2 2016 (Contd..31) 116

Products under Development by Companies, H2 2016 (Contd..32) 117

Products under Investigation by Universities/Institutes, H2 2016 118

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 119

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 120

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 121

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 122

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H2 2016 123

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H2 2016 124

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H2 2016 125

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 126

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 127

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics Sarl, H2 2016 128

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H2 2016 129

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 130

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H2 2016 131

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H2 2016 132

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H2 2016 133

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H2 2016 134

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Akinion Pharmaceuticals AB, H2 2016 135

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 136

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corp, H2 2016 137

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H2 2016 138

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express Inc, H2 2016 139

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H2 2016 140

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H2 2016 141

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea AB, H2 2016 142

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by arGEN-X BV, H2 2016 143

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H2 2016 144

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arno Therapeutics Inc, H2 2016 145

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals Inc, H2 2016 146

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Array BioPharma Inc, H2 2016 147

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc, H2 2016 148

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Asterias Biotherapeutics Inc, H2 2016 149

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 150

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca Plc, H2 2016 151

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2016 152

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Athenex Inc, H2 2016 153

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 154

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 155

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bayer AG, H2 2016 156

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BCI Pharma, H2 2016 157

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 158

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BerGenBio AS, H2 2016 159

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 160

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Path Holdings Inc, H2 2016 161

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioInvent International AB, H2 2016 162

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioLineRx Ltd, H2 2016 163

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioSight Ltd, H2 2016 164

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Blueprint Medicines Corp, H2 2016 165

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 166

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boston Biomedical Inc, H2 2016 167

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H2 2016 168

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Calithera Biosciences Inc, H2 2016 169

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2016 170

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantargia AB, H2 2016 171

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantex Pharmaceuticals Inc, H2 2016 172

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cascadian Therapeutics Inc, H2 2016 173

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celgene Corp, H2 2016 174

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellceutix Corp, H2 2016 175

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celldex Therapeutics Inc, H2 2016 176

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellectar Biosciences Inc, H2 2016 177

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellectis SA, H2 2016 178

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellerant Therapeutics Inc, H2 2016 179

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celyad SA, H2 2016 180

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CharlestonPharma LLC, H2 2016 181

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cielo Therapeutics Inc, H2 2016 182

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Constellation Pharmaceuticals Inc, H2 2016 183

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 184

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Critical Outcome Technologies Inc, H2 2016 185

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CrystalGenomics Inc, H2 2016 186

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 187

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CTI BioPharma Corp, H2 2016 188

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 189

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 190

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DC Prime BV, H2 2016 191

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 192

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DiNonA Inc, H2 2016 193

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eisai Co Ltd, H2 2016 194

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eli Lilly and Company, H2 2016 195

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Emercell SAS, H2 2016 196

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EntreChem SL, H2 2016 197

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EpiZyme Inc, H2 2016 198

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Erytech Pharma SA, H2 2016 199

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Esperance Pharmaceuticals Inc, H2 2016 200

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Exelixis Inc, H2 2016 201

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 202

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fate Therapeutics Inc, H2 2016 203

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by FLX Bio Inc, H2 2016 204

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by FORMA Therapeutics Inc, H2 2016 205

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Formula Pharmaceuticals Inc, H2 2016 206

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fortress Biotech Inc, H2 2016 207

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fujifilm Corp, H2 2016 208

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gadeta BV, H2 2016 209

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gamida Cell Ltd, H2 2016 210

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genentech Inc, H2 2016 211

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genoscience Pharma, H2 2016 212

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genosco Inc, H2 2016 213

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genzyme Corp, H2 2016 214

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gilead Sciences Inc, H2 2016 215

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H2 2016 216

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlycoMimetics Inc, H2 2016 217

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Golden Biotechnology Corp, H2 2016 218

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by H3 Biomedicine Inc, H2 2016 219

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 220

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by HEC Pharm Co Ltd, H2 2016 221

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hybrigenics SA, H2 2016 222

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Igenica Biotherapeutics Inc, H2 2016 223

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ignyta Inc, H2 2016 224

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immatics Biotechnologies GmbH, H2 2016 225

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune Pharmaceuticals Inc, H2 2016 226

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immune System Key Ltd, H2 2016 227

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunGene Inc, H2 2016 228

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ImmunoGen Inc, H2 2016 229

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Immunomedics Inc, H2 2016 230

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Incyte Corp, H2 2016 231

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Inflection Biosciences Ltd, H2 2016 232

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Interprotein Corp, H2 2016 233

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Io Therapeutics Inc, H2 2016 234

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by IPD Therapeutics BV, H2 2016 235

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jasco Pharmaceuticals LLC, H2 2016 236

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jazz Pharmaceuticals Plc, H2 2016 237

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 238

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Johnson & Johnson, H2 2016 239

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Juno Therapeutics Inc, H2 2016 240

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by JW Pharmaceutical Corp, H2 2016 241

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kainos Medicine Inc, H2 2016 242

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 243

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kiadis Pharma NV, H2 2016 244

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kite Pharma Inc, H2 2016 245

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Komipharm International Co Ltd, H2 2016 246

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 247

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Lead Discovery Center GmbH, H2 2016 248

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Les Laboratoires Servier SAS, H2 2016 249

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MacroGenics Inc, H2 2016 250

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Mateon Therapeutics Inc, H2 2016 251

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MaxCyte Inc, H2 2016 252

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by medac GmbH, H2 2016 253

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MediGene AG, H2 2016 254

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Medivation Inc, H2 2016 255

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MEI Pharma Inc, H2 2016 256

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck & Co Inc, H2 2016 257

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merck KGaA, H2 2016 258

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Merus NV, H2 2016 259

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Mesoblast Ltd, H2 2016 260

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 261

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by miRagen Therapeutics Inc, H2 2016 262

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Moleculin Biotech Inc, H2 2016 263

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by MolMed SpA, H2 2016 264

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Nanovalent Pharmaceuticals Inc, H2 2016 265

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NantKwest Inc, H2 2016 266

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Nemucore Medical Innovations Inc, H2 2016 267

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Nerviano Medical Sciences Srl, H2 2016 268

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Neumedicines Inc, H2 2016 269

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NewLink Genetics Corp, H2 2016 270

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Novartis AG, H2 2016 271

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by NuCana BioMed Ltd, H2 2016 273

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Omeros Corp, H2 2016 274

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoImmune Inc, H2 2016 275

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Onconova Therapeutics Inc, H2 2016 276

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oncopeptides AB, H2 2016 277

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoTartis Inc, H2 2016 278

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by OncoTherapy Science Inc, H2 2016 279

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oncternal Therapeutics Inc, H2 2016 280

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 281

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Otsuka Holdings Co Ltd, H2 2016 282

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Oxford BioTherapeutics Ltd, H2 2016 283

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Panther Biotechnology Inc, H2 2016 284

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Petra Pharma Corp, H2 2016 285

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pfizer Inc, H2 2016 286

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharma Mar SA, H2 2016 287

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmascience Inc, H2 2016 288

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Pharmedartis GmbH, H2 2016 289

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Philogen SpA, H2 2016 290

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Phylogica Ltd, H2 2016 291

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Polaris Pharmaceuticals Inc, H2 2016 292

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ProNAi Therapeutics Inc, H2 2016 293

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Resverlogix Corp, H2 2016 294

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Rich Pharmaceuticals Inc, H2 2016 295

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sanofi, H2 2016 296

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sareum Holdings Plc, H2 2016 297

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Seattle Genetics Inc, H2 2016 298

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Sellas Inc, H2 2016 299

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Selvita SA, H2 2016 300





List of Figures

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2016 58

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H2 2016 59

Number of Products under Development by Companies, H2 2016 60

Number of Products under Investigation by Universities/Institutes, H2 2016 78

Comparative Analysis by Late Stage Development, H2 2016 81

Comparative Analysis by Clinical Stage Development, H2 2016 82

Comparative Analysis by Early Stage Products, H2 2016 83

Assessment by Monotherapy Products, H2 2016 333

Assessment by Combination Products, H2 2016 334

Number of Products by Top 10 Targets, H2 2016 335

Number of Products by Stage and Top 10 Targets, H2 2016 335

Number of Products by Top 10 Mechanism of Actions, H2 2016 356

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 356

Number of Products by Top 10 Routes of Administration, H2 2016 378

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 378

Number of Products by Top 10 Molecule Types, H2 2016 380

Number of Products by Stage and Top 10 Molecule Types, H2 2016 380

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus